Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort study

Mette Christoffersen PhD student1, Ruth Frikke-Schmidt consultant1, Peter Schnohr consultant2, Gorm B Jensen professor23, Børge G Nordestgaard professor24, Anne Tybjærg-Hansen professor12

1Department of Clinical Biochemistry, Rigshospitalet, DK-2100 Copenhagen, Denmark; 2Copenhagen City Heart Study, Bispebjerg Hospital, DK-2400 Copenhagen; 3Department of Cardiology, Hvidovre Hospital, DK-2650 Hvidovre, Denmark; 4Department of Clinical Biochemistry, Herlev Hospital, DK-2730 Herlev, Denmark

Abstract

Objective To test the hypothesis that xanthelasma and arcus corneae, individually and combined, predict risk of ischaemic vascular disease and death in the general population.

Design Prospective population based cohort study.

Setting The Copenhagen City Heart Study.

Participants 12 745 people aged 20–93 years free of ischaemic vascular disease at baseline and followed from 1976–8 until May 2009 with 100% complete follow-up.

Main outcome measures Hazard ratios for myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and death; odds ratios for severe atherosclerosis.

Results 563 (4.4%) of participants had xanthelasma and 3159 (24.8%) had arcus corneae at baseline. During 33 years’ follow-up (mean 22 years), 1872 developed myocardial infarction, 3699 developed ischaemic heart disease, 1498 developed ischaemic stroke, 1815 developed ischaemic cerebrovascular disease, and 8507 died. Multifactorially adjusted hazard/odds ratios for people with versus those without xanthelasma were 1.48 (95% confidence interval 1.23 to 1.79) for myocardial infarction, 1.39 (1.20 to 1.60) for ischaemic heart disease, 0.94 (0.73 to 1.21) for ischaemic stroke, 0.91 (0.72 to 1.15) for ischaemic cerebrovascular disease, 1.69 (1.03 to 2.79) for severe atherosclerosis, and 1.14 (1.04 to 1.26) for death. The corresponding hazard/odds ratios for people with versus those without arcus corneae were non-significant. In people with versus those without both xanthelasma and arcus corneae, hazard/odds ratios were 1.47 (1.09 to 1.99) for myocardial infarction, 1.56 (1.25 to 1.94) for ischaemic heart disease, 0.87 (0.57 to 1.31) for ischaemic stroke, 0.86 (0.58 to 1.26) for ischaemic cerebrovascular disease, 2.75 (0.75 to 10.1) for severe atherosclerosis, and 1.09 (0.93 to 1.28) for death. In all age groups in both women and men, absolute 10 year risk of myocardial infarction, ischaemic heart disease, and death increased in the presence of xanthelasma. The highest absolute 10 years risks of ischaemic heart disease of 53% and 41% were found in men aged 70–79 years with and without xanthelasma. Corresponding values in women were 35% and 27%.

Conclusion Xanthelasma predict risk of myocardial infarction, ischaemic heart disease, severe atherosclerosis, and death in the general population, independently of well known cardiovascular risk factors, including plasma cholesterol and triglyceride concentrations. In contrast, arcus corneae is not an important independent predictor of risk.

Introduction

Xanthelasma palpebrarum are sharply demarcated, yellowish flat plaques on the upper or lower eyelids, most often near the inner canthus. Xanthelasma represents areas of macrophages containing lipids, of which the major constituent is cholesteryl esters but the exact pathophysiology is not known.1 Arcus corneae (or arcus senilis) is a grey-white-yellowish opacification located near the periphery of the cornea but separated from the limbal margin by a clear corneal zone.2 Arcus corneae represents deposits of cholesteryl ester rich lipid particles, which are thought to be selectively trapped in the extracellular matrix in the stroma of the cornea.3 Although xanthelasma and arcus corneae both consist mainly of cholesteryl esters, on average half of people presenting with xanthelasma and arcus corneae have relatively low lipid concentrations.1 3

For both xanthelasma and arcus corneae, lipids originate from plasma lipoproteins. Furthermore, similar mechanisms may be involved in the formation of xanthelasma and atherosclerotic plaques, and formation of arcus corneae can be induced by experimental hypercholesterolaemia.3 4 These findings suggest that xanthelasma and arcus corneae are markers of proatherogenic changes in the vessels and thus markers of atherosclerosis. Although most,5 12 but not all,13 14 studies have
reported increased concentrations of plasma total cholesterol or low density lipoprotein cholesterol, decreased high density lipoprotein cholesterol, or both in people with xanthelasmata, most of these case-control studies did not find any association between xanthelasmata and cardiovascular disease.\textsuperscript{3, 10-11} Similarly, arcus corneae is a well known sign of hyperlipidaemia, and some studies suggest that arcus corneae is a risk factor for cardiovascular disease,\textsuperscript{7, 11-18} although a recent study showed that this association was mainly due to an association between arcus corneae and increasing age.\textsuperscript{19} Probably because of these inconsistent results, xanthelasmata and arcus corneae are often considered benign phenomena and may not elicit further examination. However, large prospective studies examining the question of whether xanthelasmata and arcus corneae in themselves predict risk of ischaemic vascular disease and death in the general population are lacking. This is clinically important, because the visual diagnosis of xanthelasmata and arcus corneae is easy and inexpensive and can be made even in settings without access to blood samples for lipid profiles. We tested the hypothesis that xanthelasmata and arcus corneae, individually and combined, predict risk of myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, severe atherosclerosis, and death in the general population. We studied 12,745 participants from the Copenhagen City Heart Study cohort, of whom 563 (4.4%) had xanthelasmata and 3159 (24.8%) had arcus corneae at baseline, and followed them from 1976-8 until May 2009.

**Methods**

**Participants**

The Copenhagen City Heart Study is a prospective cardiovascular study of the Danish general population started in 1976-8 with follow-up examinations in 1981-3, 1991-4, and 2001-3. We invited 19,329 white women and men of Danish descent stratified into age groups of five years from 20 years to 80 years or older and drawn randomly from the Copenhagen Central Person Registry. Data came from a self-administered questionnaire, a physical examination, and blood samples. Staff checked all questionnaires during the examination in collaboration with the participant.\textsuperscript{20} Of those participants invited, 14,223 (74%) attended and we included 12,745 (66%) people for whom complete information on all relevant variables including xanthelasmata and arcus corneae were available at baseline. We followed up participants from baseline at the 1976-8 examination to the end of May 2009 by using their unique Central Person Register number. Follow-up time was 100% complete, with no participants lost to follow-up.

**Xanthelasmata and arcus corneae**

Trained nurses or medical laboratory technicians, who were unaware of the participants’ risk and disease profile, determined the presence of xanthelasmata and arcus corneae by careful visual inspection of the eyelids and the cornea during the physical examination.

**Ischaemic heart disease, ischaemic cerebrovascular disease, and death**

We collected and verified diagnoses of myocardial infarction and ischaemic heart disease (ICD-8 (international classification of diseases, 8th revision) codes 410 and 410-414; ICD-10 codes I21-I22 and I20-I25) by reviewing all hospital admissions and diagnoses entered in the national Danish Patient Registry, all causes of death entered in the national Danish Causes of Death Registry, and medical records from hospitals and general practitioners. We defined ischaemic heart disease as fatal or non-fatal myocardial infarction or characteristic symptoms of angina pectoris, including revascularisation procedures\textsuperscript{21}; death from other causes led to censoring. We determined time to ischaemic heart disease from the date of study entry until the first date of a diagnosis of either myocardial infarction or angina pectoris. Diagnosis of myocardial infarction followed the changing definitions over time. After 2000, the diagnosis was based on: either typical rise and fall of biochemical markers of myocardial necrosis (troponin or creatine kinase MB) with at least one of ischaemic symptoms, development of pathological Q waves on the electrocardiogram, and electrocardiographic changes indicative of ischaemia or coronary artery intervention; or pathological findings of an acute, healed, or healing myocardial infarction,\textsuperscript{22} with later changes as indicated.\textsuperscript{23} We gathered potential cases with ischaemic cerebrovascular disease, including ischaemic stroke, from the national Danish Patient Registry and the national Danish Causes of Death Registry (ICD-8 codes 431-438; ICD-10 codes I60-I69, G45). We requested hospital records, and experienced neurologists reviewed all potential cases. We validated possible stroke events (in patients admitted to hospital as well as non-admitted) by using the World Health Organization’s definition of stroke: an acute disturbance of focal or global cerebral function with symptoms lasting longer than 24 hours or leading to death with presumably no other reasons than of vascular origin. To distinguish between infarction (ischaemic stroke), intracerebral haemorrhage, and subarachnoid haemorrhage, a computed tomography or magnetic resonance scan, autopsy, spinal fluid examination, or surgical description was needed. The event was diagnosed as an ischaemic stroke if the scan did not show an infarction or haemorrhage but the person had symptoms that met the criteria of the definition of stroke. We did not apply the diagnosis of stroke in cases in which a scan showed signs of previous cerebrovascular disease but no history of any symptoms was present. The diagnostic criteria for ischaemic cerebrovascular disease were ischaemic stroke, transient ischaemic attack (focal neurological symptoms lasting less than 24 hours), or amaurosis fugax (transient blindness in one eye only).

Information on date of death came from the national Danish Central Person Registry, which is 100% complete.

**Severe atherosclerosis**

Ankle brachial index, a drop in blood pressure in the legs that predicts severe atherosclerosis,\textsuperscript{24-27} was determined in the 2001-3 examination of the Copenhagen City Heart Study in 2773 participants who had also participated in the baseline examination (1976-8) and had complete information on all relevant variables including xanthelasmata and arcus corneae. A standard brachial systolic and diastolic blood pressure was recorded on both arms, and systolic ankle blood pressure of the posterior tibial artery on both legs was obtained by Doppler (Huntleigh Mini Dopplex Doppler D900, Huntleigh, UK). The ankle brachial index was the lowest ankle systolic blood pressure divided by the highest brachial systolic blood pressure. Severe atherosclerosis was an ankle brachial index below 0.9.

**Lipid profile**

Enzymatic methods (Boehringer Mannheim, Mannheim, Germany) were used on fresh plasma samples to measure plasma concentrations of total cholesterol, triglycerides, and high
density lipoprotein cholesterol, the last after precipitation of lipoproteins containing apolipoprotein B. Low density lipoprotein cholesterol was calculated by using the Friedewald equation if triglycerides were below 4 mmol/L (<354.0 mg/dL) and measured directly at higher triglyceride concentrations (Thermo, Helsinki, Finland). Apolipoproteins A1 and B and lipoprotein(a) were measured by using turbidimetry (Boehringer Mannheim, Mannheim, Germany; DAKO A/S, Glostrup, Denmark, and Thermo, Helsinki, Finland).

Other covariates

Body mass index was calculated as weight in kilograms divided by height in metres squared. We defined hypertension as use of antihypertensive drugs, a systolic blood pressure of more than 140 mm Hg, or a diastolic blood pressure of more than 90 mm Hg. We defined diabetes mellitus as self reported disease, use of insulin or oral hypoglycaemic agents, or non-fasting plasma glucose concentrations of more than 11 mmol/L (>198 mg/dL). Smoking status was positive for active smokers. Pack years’ smoking was the accumulated exposure to smoking calculated from the questionnaires and categorised as 0 pack years (non-smokers and smokers who had smoked less than one pack of cigarettes a day for one month), <10 pack years (corresponding to one pack of cigarettes a day for between one month and 10 years), 10 to 20 pack years (corresponding to one pack of cigarettes a day for between 10 and 20 years), and ≥20 pack years (corresponding to one pack of cigarettes a day for 20 years or more). Regular alcohol consumers drank alcohol at least twice weekly, and light drinkers consumed alcohol less often. We defined physical inactivity as leisure time activity of less than four hours weekly. Women reported menopausal status and use of hormonal replacement therapy. We considered a family history of ischaemic vascular disease to be at least one parent with a previous myocardial infarction or ischaemic stroke. We included education and income as markers of the socioeconomic status of the participants. We dichotomised education as less than eight years of education versus at least eight years of education. We dichotomised income as a 1976-8 income of less than 10 000 Danish kroner (£1186; €1340; $1934) per month versus at least 10 000 Danish kroner per month.

Statistical analyses

We used Stata version 10.1 for all analyses. We considered two sided probability values less than 0.05 to be significant. We used the Mann-Whitney U test or Pearson χ² test in comparisons of two groups. We plotted cumulative incidences of myocardial infarction, ischaemic heart disease, and death as a function of age by using Kaplan-Meier curves and determined differences between people with and without xanthelasma by using log-rank tests. We have not shown Kaplan-Meier curves for ischaemic stroke and ischaemic cerebrovascular disease as a function of xanthelasma or all end points for arcus corneae owing to modest or no differences in cumulative incidences. We used Cox proportional hazards regression models, with age as the time scale and left truncation (delayed entry), to estimate hazard ratios for myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and death as a function of xanthelasma and arcus corneae, individually and combined. When age is used as the time scale, this implies that age is automatically adjusted for. Additional adjustments were for sex or multifactorially for sex, total cholesterol, triglycerides, body mass index, hypertension, diabetes mellitus, pack years’ smoking, alcohol consumption, physical inactivity, postmenopausal status and use of hormonal replacement therapy, family history of ischaemic vascular disease, education, and income. We examined the assumption of linearity on the log risk scale for continuous covariates (total cholesterol, triglycerides, and body mass index) by including each covariate squared, one at a time, in the fully adjusted regression models. Because of lack of complete linearity, we included these covariates as fifth in the Cox regression model. We assessed proportionality of hazards over time by plotting −ln(ln(survival)) versus ln(analyses time) and tested it by using Schoenfeld residuals. We found no major violations of the proportional hazards assumption. We accounted for competing risk of any death by censoring at the date of death. We used logistic regression models adjusted for the same covariates as above to estimate odds ratios for severe atherosclerosis (ankle brachial index <0.9 ≥0.9) as a function of presence or absence of xanthelasma and arcus corneae, individually and combined. We evaluated interaction between presence or absence of xanthelasma and other cardiovascular risk factors (sex, age <55 years ≥55 years, total cholesterol <50th centile ≥50th centile, triglycerides <50th centile ≥50th centile, body mass index <25 ≥25, hypertension yes/no, diabetes mellitus yes/no, and smoking yes/no) on risk of myocardial infarction, ischaemic heart disease, and death by the inclusion of interaction terms for two factors between xanthelasma and other risk factors one at a time in the Cox regression model, using a likelihood ratio test between models excluding and including the interaction term. For the test of interaction with age, we used years of follow-up instead of age as the time scale, analysing time to event. We have not shown stratification and test of interaction for ischaemic stroke and ischaemic cerebrovascular disease as a function of xanthelasma or all end points for arcus corneae owing to lack of effect on overall risk estimates.

We estimated absolute 10 year risks of myocardial infarction, ischaemic heart disease, and death by presence or absence of xanthelasma and age (<40 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years) by using the regression coefficients from a Poisson regression model for women and men separately and presented them as estimated incidence rates (number of events per 10 years) in percentages. We have not shown absolute 10 year risks of ischaemic stroke and ischaemic cerebrovascular disease as a function of xanthelasma or all end points for arcus corneae owing to lack of effect on overall risk estimates.

Results

Table 1 shows baseline characteristics of people from the general population by presence of xanthelasma and arcus corneae. The prevalence of xanthelasma was 4.4% and similar in women and men. The prevalence of arcus corneae was 24.8% overall but was lower in women than in men (20.1% v 30.2%; P<0.001), as previously reported. No participants were taking lipid lowering treatment at baseline in 1976-8, as this treatment was generally not implemented in Denmark until publication of the Scandinavian Simvastatin Survival Study in 1994. In total, less than 2% were taking lipid lowering treatment during follow-up after 1994.

Lipid profile

In people with xanthelasma or arcus corneae at baseline, plasma concentrations of total cholesterol, low density lipoprotein cholesterol, apolipoprotein B, and triglycerides at baseline were higher than in those without these traits (figs 1 and 2). High density lipoprotein cholesterol and apolipoprotein A1 were lower in people with xanthelasma than in those without xanthelasma, and lipoprotein(a) was higher in those...
with arcus corneae than in those without arcus corneae (figs 1 and 2).

Ischaemic heart disease, ischaemic cerebrovascular disease, and death
During a follow-up of up to 33 years (mean follow-up 22 years), 1872 participants developed myocardial infarction, 3699 developed ischaemic heart disease, 1498 developed ischaemic stroke, 1815 developed ischaemic cerebrovascular disease, and 8507 died. For myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and total death, the incidence rates in events per 10 000 person years were 121, 226, 64, 74, and 414 in people with xanthelasma and 65, 134, 53, 65, and 293 in those without xanthelasma (table 2). Multifactorially adjusted (age, sex, total cholesterol, triglycerides, body mass index, hypertension, diabetes, pack years’ smoking, alcohol consumption, physical activity, postmenopausal status, hormonal replacement therapy, education, income, and family history of ischaemic vascular disease) hazard ratios were 1.48 (95% confidence interval 1.23 to 1.79) for myocardial infarction, 1.39 (1.20 to 1.60) for ischaemic heart disease, 0.94 (0.73 to 1.21) for ischaemic stroke, 0.91 (0.72 to 1.15) for ischaemic cerebrovascular disease, and 1.14 (1.04 to 1.26) for total death (table 2). For myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and total death, the incidence rates in events per 10 000 person years were 110, 236, 83, 101, and 510 in people with arcus corneae and 57, 115, 47, 57, and 247 in those without arcus corneae (table 3). After multifactorial adjustment, no hazard ratios remained significant.

In people with versus those without both xanthelasma and arcus corneae, multifactorially adjusted hazard ratios were 1.47 (1.09 to 1.99) for myocardial infarction, 1.56 (1.25 to 1.94) for ischaemic heart disease, 0.87 (0.57 to 1.31) for ischaemic stroke, 0.86 (0.58 to 1.26) for ischaemic cerebrovascular disease, and 1.09 (0.93 to 1.28) for total death (table 4). We found no interaction between xanthelasma and arcus corneae on risk of any end point. The cumulative incidence of myocardial infarction, ischaemic heart disease, and death was higher in people with versus those without xanthelasma (all log-rank tests, P<0.001) (fig 3). The median survival time (that is, the age at which 50% were still alive) was 75 years in people with xanthelasma compared with 78 years in those without xanthelasma (P<0.001).

We found statistical evidence for an interaction between xanthelasma and sex on risk of myocardial infarction (multifactorially adjusted P=0.04) and risk of ischaemic heart disease (P=0.04) and between xanthelasma and age on risk of myocardial infarction (P=0.01) and risk of ischaemic heart disease (P=0.04) (fig 4). In women, xanthelasma was a slightly better predictor of myocardial infarction and ischaemic heart disease than it was in men; in people aged under 55, xanthelasma was a slightly better predictor of myocardial infarction and ischaemic heart disease than it was in those aged 55 or over.

Severe atherosclerosis
Ankle brachial index, a drop in blood pressure in the legs that predicts severe atherosclerosis, was measured at the 2001-3 examination. Of 2773 people who attended both the 1976-8 and 2001-3 examinations of the Copenhagen City Heart Study, 757 had xanthelasma and 249 had arcus corneae at baseline, and 647 had an ankle brachial index below 0.9 indicating severe atherosclerosis (table 5). Mean ankle brachial index was lower in people with xanthelasma or arcus corneae than in those without (P<0.01; table 5, third column). Thirty-nine per cent of people with xanthelasma had an ankle brachial index below 0.9, indicating severe atherosclerosis, compared with 23% of those without xanthelasma. Corresponding values were 34% and 22% in people with and without arcus corneae (P<0.01; table 5, right column).

Multifactorially adjusted odds ratio for severe atherosclerosis in people with versus those without xanthelasma was 1.69 (1.03 to 2.79) (table 2). Arcus corneae was not associated with increased risk of severe atherosclerosis (table 3).

Absolute 10 year risk of myocardial infarction, ischaemic heart disease, and total death
We further examined the significant associations between xanthelasma and risk of myocardial infarction, ischaemic heart disease, and total death by calculating absolute 10 year risks. In all age groups in both women and men, absolute 10 year risk of myocardial infarction, ischaemic heart disease, and total death increased in the presence of xanthelasma (table 6). The highest absolute 10 year risks of myocardial infarction of 28% and 19% were in men aged 70-79 years with and without xanthelasma. Equivalent values in women were 14% and 9%. For ischaemic heart disease, corresponding values were 53% and 41% in men and 35% and 27% in women. The absolute 10 year risks of total death were higher than those for myocardial infarction and ischaemic heart disease, but the absolute increase in risk in people with versus those without xanthelasma was slightly attenuated compared with those for myocardial infarction and ischaemic heart disease.

Discussion
The principal finding of this study of 12 745 people from the Danish general population followed from 1976-8 to 2009 is that presence of xanthelasma in itself predicts risk of myocardial infarction, ischaemic heart disease, severe atherosclerosis, and death in the general population independent of well known cardiovascular risk factors, including plasma cholesterol and triglyceride concentrations. In contrast, arcus corneae is not an important independent predictor of risk. These findings are novel.

Comparison with other studies
This prospective study is substantially larger than previous studies. A study of 100 patients with xanthelasma attending a dermatology outpatient clinic and 100 matched controls found no increased risk of cardiovascular disease associated with xanthelasma.14 In support of our findings, xanthelasma have previously been shown to be a predictor of future death among 1712 Italian men in a prospective study at both 25 and 30 years of follow-up.32 33 A possible explanation for the increased risk of myocardial infarction and ischaemic heart disease as well as the reduced longevity predicted by the presence of xanthelasma may be an increased propensity of these people to deposit cholesterol in connective tissues of the body. This could be due to increased leakage of cholesterol from the vessels, increased retention of cholesterol in the connective tissue of both the arterial intima and the dermis, increased uptake of cholesterol in macrophages, and combinations of these factors and other factors as well.1
in women than in men, and in those aged under 55 years compared with those aged 55 and over. This might be explained by the fact that male sex and age are both well known risk factors for myocardial infarction and ischaemic heart disease, so the presence of xanthelasmata just adds to this predetermined risk in men and in older people. In women, who have a smaller inherent risk of developing myocardial infarction and ischaemic heart disease, presence of xanthelasmata has a correspondingly larger predictive value. Importantly, our results show that although mean concentrations of cholesterol and triglycerides were higher in people with xanthelasmata than in those without xanthelasmata at baseline, xanthelasmata predicted similar increases in risk for myocardial infarction and ischaemic heart disease in those with concentrations of cholesterol and triglycerides below the 50th centile and at or above the 50th centile. This is a question that has been debated extensively, as most previous work has focused on differences between hyperlipidaemic and normolipidaemic people with xanthelasmata. Our results clearly establish for the first time that people with xanthelasmata have an increased risk of cardiovascular disease regardless of plasma cholesterol and triglyceride concentrations. This implies that our hypothesised increased tendency for people with xanthelasmata to deposit cholesterol in tissues is largely independent of plasma concentrations of these lipids.

We calculated the absolute 10 year risk of ischaemic heart disease in people with xanthelasmata and found that it approaches or exceeds 20% in several age groups of both sexes. People with an absolute 10 year risk of ischaemic heart disease above 20% are generally considered to be at high risk, and recommendations for treatment include both lifestyle changes and treatment to reduce low density lipoprotein cholesterol. The absolute 10 year risk estimates for myocardial infarction, ischaemic heart disease, and total death as a function of presence of xanthelasmata stratified for age and sex allows clinicians to use presence of xanthelasmata together with age and sex in the assessment of risk in individual patients.

Presence of arcus corneae was associated with an increased risk of myocardial infarction, ischaemic heart disease, and total death after adjustment for only age and sex. However, arcus corneae did not remain a risk predictor after multifactorial adjustment. In support of these findings, a recent prospective study with eight years of follow-up reported a trend towards a significant association between arcus corneae and cardiovascular disease after adjustment for age and sex, which disappeared after additional adjustment for well known cardiovascular risk factors. Thus, presence of arcus corneae seems to reflect an adverse cardiovascular risk profile—probably in particular an unfavourable lipid profile. This is supported by the higher prevalence of arcus corneae in men, who have a larger inherent risk of cardiovascular disease.

Implications for clinicians and policymakers

The results from this study suggest that xanthelasmata are a cutaneous marker of atherosclerosis independent of lipid concentrations and thus should be considered in clinical practice as an independent and additional risk factor for myocardial infarction and ischaemic heart disease. Today, most people with xanthelasmata are seen by dermatologists, when they want their xanthelasmata removed for cosmetic reasons. Because of the lack of consensus on the clinical importance of xanthelasmata, some of these people may not have been managed according to their increased risk of cardiovascular disease. The findings from our study could be of particular value in societies where access to laboratory facilities, and thus lipid profile measurement, is difficult. In this setting, presence of xanthelasmata may be a useful predictor of underlying atherosclerotic disease. An easy registration of presence of xanthelasmata along with age and sex makes it possible to assess the risk of myocardial infarction and ischaemic heart disease and thus to make sure that people at increased risk are managed accordingly with lifestyle changes and treatment to reduce low density lipoprotein cholesterol.

Strengths and limitations of study

Our study has several strengths. We studied a homogeneous white general population of 100% Danes; we had a 66% participation rate and up to 33 years of complete follow-up. For all participants, complete information on all variables was available at baseline, and we had sufficient statistical power to examine even the association between xanthelasmata and risk of ischaemic vascular disease and total death in different subgroups of our study population. Moreover, no participants were using lipid lowering treatment at baseline in 1976-8, so none of the lipid profiles of the participants are biased by effects of treatment. This makes this study unique in its ability to evaluate the association between xanthelasmata, arcus corneae, lipid concentrations, and risk of cardiovascular disease.

A limitation to the generalisability of our study is that we examined only white people. The prevalence of xanthelasmata and arcus corneae, as well as the association with risk of cardiovascular disease, may differ among different ethnicities. Therefore, our findings may not necessarily translate to populations of other ethnicities. Another limitation is that the diagnosis of xanthelasmata and arcus corneae was based on visual inspection. Overlooking mild cases of xanthelasmata and arcus corneae is of course a possibility, which could have led to an underestimation of risk of disease and death. The opposite situation—misclassification of people free of xanthelasmata and arcus corneae—is probably less likely, as both of these deposits are relatively easy to diagnose visually and the investigators were specifically trained for this. Furthermore, the prevalence of xanthelasmata and arcus corneae in our study corresponds well with previous reports in the literature. Finally, although we have adjusted for a large number of covariates, unmeasured confounders may still have influenced our results. In particular, low density lipoprotein cholesterol, high density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins were not measured at baseline in 1976-8 and thus were not adjusted for. However, we adjusted for total cholesterol (that is, cholesterol in low density lipoprotein, high density lipoprotein, remnants, and lipoprotein(a)) and for non-fasting triglycerides. In addition, we adjusted for baseline measurements of all confounders, although some confounders may have changed during the follow-up period of up to 33 years.

Conclusion

We have shown that xanthelasmata predict increased risk of myocardial infarction, ischaemic heart disease, and total death independently of well known cardiovascular risk factors, including plasma cholesterol and triglyceride concentrations. In contrast, arcus corneae is not an important independent risk predictor.

We thank the staff and participants from the Copenhagen City Heart Study for their important contributions to our study.

Contributors: All authors contributed to the study design and had full access to all the data in the study. MC, RF-S, BGN, and AT-H analysed and interpreted the data. PS and GBj contributed to the collection of data, through initiation of the Copenhagen City Heart Study. MC and
What is already known about this topic

Xanthelasma and arcus corneae are associated with increased concentrations of plasma total or low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein, or both

Most previous studies have shown no associations between xanthelasmas or arcus corneae and risk of myocardial infarction and ischaemic heart disease, but the results are inconsistent, and few prospective studies exist.

Consensus on the clinical importance of xanthelasma and arcus corneae is absent

What this study adds

Xanthelasma, but not arcus corneae, predicts increased risk of myocardial infarction, ischaemic heart disease, and total death independently of well known cardiovascular risk factors, including plasma cholesterol and triglyceride concentrations

People with xanthelasma and relatively low lipid concentrations are at an increased risk of myocardial infarction, ischaemic heart disease, and early death, independent of their lipid profiles

Arcus corneae is not an important independent risk predictor

AT-H drafted the report (with significant contributions from all other authors). All authors have seen and approved the final version of the report. MC and AT-H are the guarantors.

Funding: This study was funded by the Research Fund at Rigshospitalet, the Lundbeck Foundation, the Danish Medical Research Council, and the Danish Heart Foundation. The sponsors had no role in the design of the study; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

The views expressed in this paper are those of the authors and not those of any funding body or others whose support is acknowledged.

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: The study was approved by institutional review boards and by Danish ethical committees (the Copenhagen and Frederiksborg committee and the Copenhagen committee; KF-100.2039/91, KF-01-144/01, H-KF-01-144/01). Participants gave written informed consent.

Data sharing: No additional data available.

1 Bergman R. The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 1994;30:236-42.
2 Fernández-Soriano A, Thompson PD. Corneal arcus as coronary artery disease risk factor. Atherosclerosis 2007;193:235-40.
3 Sagal P, Insulw Jr, Chambless LE, Stinnett S, LaRosa JC, Weissfeld L, et al. The association of dyslipoproteinemia with corneal arcus and xanthelasma. The Lipid Research Clinics Program Prevalence Study. Circulation 1986;73:1108-18.
4 Parker FS, Ofstad GF. Experimental xanthoma: a correlative biochemical, histological, and electron microscopic study. Am J Pathol 1968;53:537-65.
5 Kahán A, Káhn L, Timár V. Lipid anomalies in cases of xanthelasma. Am J Ophthalmol 1967;63:320-5.
6 Bailey MC, Warren SG. Xanthelasma: clinical indicator of decreased levels of high-density lipoprotein cholesterol. South Med J 1989;82:570-4.
7 Watanabe A, Yoshimura A, Wakasugi T, Tatami R, Ueda K, Ueda R, et al. Serum lipids, lipoprotein lipids and coronary heart disease in patients with xanthelasma. Atherosclerosis 1981;38:293-8.
8 Ribera M, Pintó X, Argimon JM, Fiol C, Pujol R, Ferrándiz C. Lipid metabolism and apolipoprotein E phenotypes in patients with xanthelasma. Am J Med 1995;99:485-90.
9 Tursun Ü, Eskandari G, Kaygılı T, Tamer L, Bilgiz G, Ali U. Apolipoprotein E polymorphism and lipoprotein composition in normolipidemic xanthelasma patients. J Eur Acad Dermatol Venereol 2006;20:280-3.
10 Chan CC, Lin SJ, Hwang JJ, Sun CC, Jeng JS, Hwang BS, et al. Xanthelasma palpebrarum is not associated with increased risk of carotid atherosclerosis in normolipidemia. Int J Clin Pract 2008;62:221-7.
11 Özdoğan S, Şahin S, Tokgozlu L. Xanthelasma palpebrarum and its relation to atherosclerotic risk factors and lipoprotein(a). Int J Dermatol 2008;47:785-9.
12 Pedace FJ, Winkelman RK. Xanthelasma palpebrarum. JAMA 1965;193:893-4.
13 Jönsson A, Sigfusson N. Significance of xanthelasma palpebrarum in the normal population. Lancet 1976;1:372.
14 Noll B. Premature atherosclerosis in patients with xanthelasma. J Eur Acad Dermatol Venereol 2007;21:1244-8.
15 Ritkind BM. The incidence of arcus senilis in ischaemic heart disease: its relation to serum lipid levels. Lancet 1965;1:1312-4.
16 Klein B, Klein R, Haseman J, Maready H, James C. Corneal arcus and cardiovascular disease in Evans County, Georgia. Arch Intern Med 1975;135:509-11.
17 Rosenman RH, Brand RJ, Bathish RR, Jenkins D. Relation of corneal arcus to cardiovascular risk factors and the incidence of coronary disease. N Engl J Med 1974;291:1322-4.
18 Piré J, Vidalut J, Haffen ST, Eisenberg H. Association between corneal arcus and some of the factors for coronary artery disease. Br J Ophthalmol 1983;67:795-8.
19 Fernandez AB, Kayes MJ, Perinada M, D’Agostino R, O’Donnell CJ, Thompson PD. Relation of corneal arcus to cardiovascular disease (from the Framingham Heart Study data set). Am J Cardiol 2006;103:64-6.
20 Schnor P, Jensen JS, Schlarhing H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community: a 21 year follow-up of 12 000 men and women from the Copenhagen City Heart Study. Eur Heart J 2002;23:620-6.
21 Fox K, García MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006;27:1341-81.
22 The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000;21:1502-13.
23 Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38.
24 Eldög N, Sillesen H, Proctor E, Nordestgaard BG. Artrial branchial index, C-reactive protein, and central augmentation index to identify individuals with severe atherosclerosis. Eur Heart J 2006;27:1316-22.
25 Criqui MH, Langer RD, Fronick A, Feigelson HS, Klaber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:361-6.
26 Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med 2003;163:1939-42.
27 Newman AB, Shemanski L, Manolio TA, Cushman M, Mittsick M, Polak JF, et al. Artrial-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:538-45.
28 Friedwald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
29 Kastrup P, Bøn M, Tyberg Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008;117:176-84.
30 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
31 Langsted A, Freiberg JJ, Tyberg Hansen A, Schnurr P, Jensen GB, Nordestgaard BG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011;269:65-75.
32 Mendotti A, Mariotti S, Secareccia F, Torsello S, Dima F. Determinants of all causes of death in samples of Italian middle-aged men followed up for 25 years. J Epidemiol Community Health 1987;41:243-50.
33 Mendotti A, Giampad S, Secareccia F. The relationship of cardiovascular risk factors measured at different ages to prediction of all-cause mortality and longevity. Arch Gerontol Geriatr 1989;28:99-111.
34 Doussé-Blazy P, Marol YL, Cohen L, Giroux JM, Davignon J. Increased frequency of Apo E-ED phenotype and hyperapobetalipoproteinemia in normolipidemic subjects with xanthelasmas of the eyelid. Ann Intern Med 1988;108:164-9.
35 National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)—final report. Circulation 2002;106:314-42.

Accepted: 14 July 2011

Cite this as: BMJ 2011;343:d5497

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
### Tables

| Characteristic                                | Xanthelasma | Arcus corneae |
|-----------------------------------------------|-------------|---------------|
|                                              | Yes         | No            | Yes | No |
| Observations                                 | 563 (4.4)   | 12 182 (95.6) | 3159 (24.8) | 9588 (75.2) |
| Median (interquartile range) age (years)      | 57 (50-64)* | 53 (44-60)    | 61 (55-67)* | 50 (41-58)  |
| Female sex                                   | 305 (54)    | 6533 (54)     | 1375 (44)*  | 5467 (57)   |
| Median (interquartile range) total cholesterol (mmol/L) | 6.2 (5.6-7.2)* | 6.0 (5.2-6.8) | 6.3 (5.6-7.1)* | 5.9 (5.2-6.7) |
| Median (interquartile range) triglycerides (mmol/L) | 1.6 (1.2-2.3)* | 1.4 (1.0-2.1) | 1.5 (1.1-2.2)* | 1.4 (1.0-2.0) |
| Median (interquartile range) body mass index (kg/m²) | 26 (23-28)* | 25 (22-27) | 25 (23-28)* | 24 (22-27) |
| Hypertension†                                 | 322 (57)*   | 5858 (48)     | 1963 (62)*  | 4217 (44)   |
| Diabetes mellitus‡                            | 20 (4)      | 338 (3)       | 140 (4)*    | 218 (2)     |
| Active smoker                                 | 383 (68)§   | 7673 (63)     | 2052 (65)§  | 6004 (63)   |
| Median (interquartile range) pack years’ smoking¶ | 15 (0-30)*  | 10 (0-25)     | 15 (0-33)*  | 10 (0-23)   |
| Regular alcohol consumer**                   | 272 (48)    | 6345 (52)     | 1697 (54)§  | 4920 (51)   |
| Physically inactive††                         | 450 (80)§   | 8937 (73)     | 2379 (75)§  | 7009 (73)   |
| Postmenopausal                                | 230 (75)§   | 4331 (66)     | 1269 (92)*  | 3292 (60)   |
| Hormonal replacement therapy                  | 56 (24)     | 964 (22)      | 216 (17)*   | 804 (24)    |
| Lipid lowering treatment                      | 0           | 0             | 0           | 0           |
| Family history of ischaemic vascular disease‡‡ | 192 (46)    | 4113 (42)     | 1021 (44)   | 3092 (42)   |
| Education <8 years                            | 322 (57)*   | 5730 (47)     | 1798 (57)*  | 4254 (44)   |
| Income <10 000 DKK/month                      | 457 (81)    | 9736 (80)     | 2659 (84)*  | 7534 (79)   |

*P<0.001 by Mann-Whitney U test or Pearson χ² test.
†Use of antihypertensive drugs, systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mm Hg.
‡Self reported disease, use of insulin or oral hypoglycaemic agents, or non-fasting plasma glucose concentrations >11 mmol/L (>198 mg/dL).
§P<0.05 by Mann-Whitney U test or Pearson χ² test.
¶Accumulated smoking exposure calculated from questionnaires.
**At least twice weekly.
††Leisure time activity <4 hours weekly.
‡‡At least one parent with previous myocardial infarction or ischaemic stroke.
Table 2: Hazard/odds ratios for ischaemic vascular disease, total death, and severe atherosclerosis (ankle brachial index (ABI) <0.9 v ≥0.9) by presence or absence of xanthelasmata

| End point                          | No of participants | No of events | Events/10 000 person years (95% CI) | Hazard/odds ratios* (95% CI) | Age and sex adjusted | Multifactorially adjusted† |
|-----------------------------------|--------------------|-------------|-------------------------------------|-----------------------------|----------------------|---------------------------|
| Myocardial infarction:            |                    |             |                                     |                             |                      |                           |
| No xanthelasmata                  | 12 182             | 1749        | 65 (62 to 69)                       | 1.48 (1.23 to 1.79)         | 1                    | 1                         |
| Xanthelasmata                     | 563                | 123         | 121 (101 to 144)                    | 1.67 (1.39 to 2.00)         | 1.48 (1.23 to 1.79)  |                           |
| Ischaemic heart disease:          |                    |             |                                     |                             |                      |                           |
| No xanthelasmata                  | 12 182             | 3482        | 134 (130 to 139)                    | 1.39 (1.20 to 1.60)         | 1                    | 1                         |
| Xanthelasmata                     | 563                | 217         | 226 (197 to 258)                    | 1.52 (1.32 to 1.74)         | 1.39 (1.20 to 1.60)  |                           |
| Ischaemic stroke:                 |                    |             |                                     |                             |                      |                           |
| No xanthelasmata                  | 12 182             | 1431        | 53 (51 to 56)                       | 1.05 (0.82 to 1.34)         | 0.94 (0.73 to 1.21)  |                           |
| Xanthelasmata                     | 563                | 67          | 64 (49 to 81)                       |                             |                      |                           |
| Ischaemic cerebrovascular disease:|                    |             |                                     |                             |                      |                           |
| No xanthelasmata                  | 12 182             | 1738        | 65 (62 to 68)                       | 1.00 (0.79 to 1.25)         | 0.91 (0.72 to 1.15)  |                           |
| Xanthelasmata                     | 563                | 77          | 74 (59 to 93)                       |                             |                      |                           |
| Total deaths:                     |                    |             |                                     |                             |                      |                           |
| No xanthelasmata                  | 12 182             | 8061        | 293 (287 to 300)                    | 1.25 (1.14 to 1.38)         | 1.14 (1.04 to 1.26)  |                           |
| Xanthelasmata                     | 563                | 446         | 414 (376 to 454)                    |                             |                      |                           |
| Severe atherosclerosis (ABI <0.9 v ≥0.9): |              |             |                                     |                             |                      |                           |
| No xanthelasmata                  | 2098               | 618         | –                                   | 1.76 (1.08 to 2.85)         | 1.69 (1.03 to 2.79)  |                           |
| Xanthelasmata                     | 75                 | 29          | –                                   |                             |                      |                           |

*Hazard ratios for myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and total death from Copenhagen City Heart Study 1976-8 examination (n=12 745; follow-up up to 33 years, mean follow-up 22 years); odds ratios for severe atherosclerosis (ABI <0.9 v ≥0.9) from Copenhagen City Heart Study 2001-3 examination.

†Adjusted for age, sex, total cholesterol, triglycerides, body mass index, hypertension, diabetes, pack years' smoking, alcohol consumption, lipid lowering treatment, physical inactivity, education, income, family history of ischaemic vascular disease, and in women also for postmenopausal status and hormonal replacement therapy.
| End point | No of participants | No of events | Events/10 000 person years (95% CI) | Hazard/odds ratios* (95% CI) | Age and sex adjusted | Multifactorially adjusted† |
|-----------|--------------------|--------------|-----------------------------------|-----------------------------|----------------------|--------------------------|
| **Myocardial infarction:** | | | | | | |
| No arcus corneae | 9586 | 1289 | 57 (54 to 61) | 1 | 1 |
| Arcus corneae | 3159 | 583 | 110 (101 to 120) | 1.15 (1.04 to 1.27) | 0.97 (0.88 to 1.08) |
| **Ischaemic heart disease:** | | | | | | |
| No arcus corneae | 9586 | 2513 | 115 (111 to 120) | 1 | 1 |
| Arcus corneae | 3159 | 1186 | 236 (223 to 250) | 1.18 (1.10 to 1.27) | 1.06 (0.98 to 1.14) |
| **Ischaemic stroke:** | | | | | | |
| No arcus corneae | 9586 | 1057 | 47 (44 to 50) | 1 | 1 |
| Arcus corneae | 3159 | 441 | 83 (76 to 91) | 0.98 (0.87 to 1.10) | 0.90 (0.80 to 1.01) |
| **Ischaemic cerebrovascular disease:** | | | | | | |
| No arcus corneae | 9586 | 1285 | 57 (54 to 60) | 1 | 1 |
| Arcus corneae | 3159 | 530 | 101 (93 to 110) | 0.98 (0.89 to 1.09) | 0.90 (0.81 to 1.00) |
| **Total deaths:** | | | | | | |
| No arcus corneae | 9586 | 5710 | 247 (241 to 254) | 1 | 1 |
| Arcus corneae | 3159 | 2797 | 510 (491 to 529) | 1.09 (1.04 to 1.14) | 1.02 (0.97 to 1.07) |
| **Severe atherosclerosis (ABI <0.9 v ≥0.9):** | | | | | | |
| No arcus corneae | 2524 | 562 | – | 1 | 1 |
| Arcus corneae | 249 | 85 | – | 1.27 (1.04 to 1.70) | 1.25 (0.92 to 1.70) |

*Hazard ratios for myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and total death from Copenhagen City Heart Study 1976-8 examination (n=12 745; follow-up up to 33 years, mean follow-up 22 years); odds ratios for severe atherosclerosis (ABI <0.9 v ≥0.9) from Copenhagen City Heart Study 2001-3 examination.

†Adjusted for age, sex, total cholesterol, triglycerides, body mass index, hypertension, diabetes, pack years’ smoking, alcohol consumption, lipid lowering treatment, physical inactivity, education, income, family history of ischaemic vascular disease, and in women also for postmenopausal status and hormonal replacement therapy.
| End point                      | No of participants | No of events | Events/10 000 person years (95% CI) | Age and sex adjusted | Multifactorially adjusted† |
|-------------------------------|--------------------|--------------|-----------------------------------|----------------------|---------------------------|
| Myocardial infarction:        |                    |              |                                   |                      |                           |
| Neither xanthelasma nor arcus cornea | 9202 | 1211 | 56 (53 to 59) | 1 | 1 |
| Only arcus cornea           | 2980 | 538  | 107 (98 to 117) | 1.14 (1.03 to 1.27) | 0.97 (0.87 to 1.08) |
| Only xanthelasma            | 384  | 78   | 104 (82 to 130) | 1.67 (1.33 to 2.11) | 1.43 (1.14 to 1.81) |
| Both xanthelasma and arcus cornea | 179 | 45   | 167 (122 to 224) | 1.86 (1.38 to 2.50) | 1.47 (1.09 to 1.99) |
| Ischaemic heart disease:     |                    |              |                                   |                      |                           |
| Neither xanthelasma nor arcus cornea | 9202 | 2383 | 113 (108 to 117) | 1 | 1 |
| Only arcus cornea           | 2980 | 1099 | 230 (217 to 244) | 1.17 (1.08 to 1.25) | 1.05 (0.97 to 1.13) |
| Only xanthelasma            | 384  | 130  | 182 (152 to 216) | 1.45 (1.22 to 1.73) | 1.32 (1.10 to 1.58) |
| Both xanthelasma and arcus cornea | 179 | 87   | 353 (283 to 436) | 1.85 (1.50 to 2.30) | 1.56 (1.25 to 1.94) |
| Ischaemic stroke:            |                    |              |                                   |                      |                           |
| Neither xanthelasma nor arcus cornea | 9202 | 1014 | 47 (44 to 49)  | 1 | 1 |
| Only arcus cornea           | 2980 | 417  | 83 (75 to 91)   | 0.98 (0.87 to 1.10) | 0.90 (0.80 to 1.01) |
| Only xanthelasma            | 384  | 43   | 56 (40 to 75)   | 1.04 (0.77 to 1.42) | 0.92 (0.67 to 1.26) |
| Both xanthelasma and arcus cornea | 179 | 24   | 86 (55 to 128)  | 1.04 (0.69 to 1.56) | 0.87 (0.57 to 1.31) |
| Ischaemic cerebrovascular disease: |          |              |                                   |                      |                           |
| Neither xanthelasma nor arcus cornea | 9202 | 1235 | 57 (54 to 60)  | 1 | 1 |
| Only arcus cornea           | 2980 | 503  | 101 (93 to 111) | 0.98 (0.88 to 1.09) | 0.90 (0.80 to 1.00) |
| Only xanthelasma            | 384  | 50   | 66 (49 to 86)   | 1.00 (0.76 to 1.33) | 0.89 (0.67 to 1.19) |
| Both xanthelasma and arcus cornea | 179 | 27   | 98 (65 to 143)  | 0.98 (0.67 to 1.43) | 0.86 (0.58 to 1.26) |
| Total deaths:                |                    |              |                                   |                      |                           |
| Neither xanthelasma nor arcus cornea | 9202 | 5426 | 243 (237 to 250) | 1 | 1 |
| Only arcus cornea           | 2980 | 2635 | 507 (488 to 527) | 1.09 (1.04 to 1.15) | 1.02 (0.97 to 1.07) |
| Only xanthelasma            | 384  | 284  | 359 (318 to 403) | 1.29 (1.14 to 1.45) | 1.19 (1.05 to 1.34) |
| Both xanthelasma and arcus cornea | 179 | 162  | 564 (481 to 658) | 1.29 (1.10 to 1.51) | 1.09 (0.93 to 1.28) |
| Severe atherosclerosis (ABI <0.9 v ≥0.9): |         |              |                                   |                      |                           |
| Neither xanthelasma nor arcus cornea | 2459 | 538  | –                  | 1 | 1 |
| Only arcus cornea           | 239  | 80   | –                  | 1.26 (0.93 to 1.70) | 1.23 (0.90 to 1.68) |
| Only xanthelasma            | 65   | 24   | –                  | 1.73 (1.03 to 2.93) | 1.51 (0.87 to 2.63) |
| Both xanthelasma and arcus cornea | 10  | 5    | –                  | 2.34 (0.67 to 8.21) | 2.75 (0.75 to 10.1) |

*Hazard ratios for myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and total death from Copenhagen City Heart Study 1976-8 examination (n=12 745; follow-up up to 33 years, mean follow-up 22 years); odds ratios for severe atherosclerosis (ABI <0.9 v ≥0.9) from Copenhagen City Heart Study 2001-3 examination.

†Adjusted for age, sex, total cholesterol, triglycerides, body mass index, hypertension, diabetes, pack years’ smoking, alcohol consumption, lipid lowering treatment, physical inactivity, education, income, family history of ischaemic vascular disease, and in women also for postmenopausal status and hormonal replacement therapy.
Table 5 | Ankle brachial index (ABI) as continuous variable or proportion with ABI <0.9 (severe atherosclerosis) in people with or without baseline xanthelasmata or arcus corneae at 2001-3 examination of Copenhagen City Heart Study

| Group               | No of participants | Mean (SE) ankle brachial index | No (%) of participants with ABI <0.9 |
|---------------------|--------------------|-------------------------------|-------------------------------------|
| No xanthelasmata    | 2698               | 0.99 (0.003)                  | 618 (23)                            |
| Xanthelasmata       | 75                 | 0.93 (0.02)*                  | 29 (39)*                            |
| No arcus corneae    | 2524               | 0.99 (0.003)                  | 562 (22)                            |
| Arcus corneae       | 249                | 0.95 (0.01)*                  | 85 (34)*                            |

*P<0.01 by Mann-Whitney U test or Pearson χ² test when comparing people with or without xanthelasmata or arcus corneae.
|                        | Women (10 year age groups) |                        | Men (10 year age groups) |                        |
|------------------------|-----------------------------|------------------------|--------------------------|------------------------|
|                        | <40  | 40-49 | 50-59 | 60-69 | 70-79 | <40  | 40-49 | 50-59 | 60-69 | 70-79 |
| **Myocardial infarction** |      |       |       |       |       |      |       |       |       |       |
| No xanthelasmata       | 1.2  | 2.9   | 5.2   | 7.8   | 9.2   | 2.7  | 6.3   | 11.1  | 16.1  | 19.1  |
| xanthelasmata          | 1.5  | 3.3   | 5.7   | 8.6   | 11.1  | 3.2  | 7.0   | 12.1  | 18.1  | 23.1  |
| **Ischaemic heart disease** |      |       |       |       |       |      |       |       |       |       |
| No xanthelasmata       | 3.1  | 6.9   | 11.1  | 18.1  | 27.27 | 29.2 | 6.1   | 19.1  | 30.1  | 41.1  |
| xanthelasmata          | 3.6  | 7.4   | 11.1  | 17.1  | 27.1  | 40.1 | 9.1   | 18.1  | 28.1  | 42.1  |
| **Overall death**      |      |       |       |       |       |      |       |       |       |       |
| No xanthelasmata       | 5.1  | 14.1  | 25.3  | 26.3  | 38.37 | 51.48 | 6.1   | 20.19 | 34.33 | 50.49 |
| xanthelasmata          | 5.7  | 15.1  | 27.23 | 19.44 | 44.44 | 50.61 | 7.6   | 23.66 | 39.56 | 56.56 |

*From 1976-8 examination (n=12,745; follow-up up to 33 years, mean follow-up 22 years).  
†P<0.001 when testing for trend in absolute 10 year risk across age groups.  
‡P<0.05 when testing for trend in absolute 10 year risk across age groups.  
§P<0.001 when comparing people with and without baseline xanthelasmata.  
¶P<0.05 when comparing people with and without baseline xanthelasmata.
Figures

1976-8

1981-3

1991-4

2001-3

Total cholesterol (mmol/L)

LDL cholesterol (mmol/L)

Triglycerides (mmol/L)

Apolipoprotein B (mg/dL)

Apolipoprotein A1 (mg/dL)

Lipoprotein (a) (mg/dL)

Not done

P=0.001

Not done

P=0.001

Not done

P=0.33

Not done

P=0.01

Not done

P=0.17

Not done

P=0.02

Not done

P=0.004

Not done

P=0.11

Not done

P=0.04

Not done

P=0.15

Not done

P=0.84

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15

No statins users

P=0.01

P=0.04

P=0.03

P=0.02

P=0.11

P=0.15
**Fig 1** Mean plasma concentrations of lipids, lipoproteins, and apolipoproteins in people with or without baseline xanthelasmata at the 1976-8, 1981-3, 1991-3, and 2001-3 examinations of Copenhagen City Heart Study. Error bars represent standard errors of the mean. HDL=high density lipoprotein; LDL=low density lipoprotein.
Fig 2 Mean plasma concentrations of lipids, lipoproteins, and apolipoproteins in people with or without baseline arcus corneae at the 1976-8, 1981-3, 1991-3, and 2001-3 examinations of Copenhagen City Heart Study. Error bars represent standard errors of the mean. HDL=high density lipoprotein; LDL=low density lipoprotein.
Fig 3 Cumulative incidences of myocardial infarction, ischaemic heart disease, and total death in Copenhagen City Heart Study in people with or without xanthelasmata. Dotted lines indicate median survival time in people with and without xanthelasmata.
Fig 4 Risk of myocardial infarction, ischaemic heart disease, and total death in Copenhagen City Heart Study in people with versus those without xanthelasmata stratified by cardiovascular risk factors. Hazard ratios are from 1976-8 examination (n=12 745; follow-up up to 33 years, mean follow-up 22 years). Adjustment was for age, sex, total cholesterol, triglycerides, body mass index, hypertension, diabetes, pack years’ smoking, alcohol consumption, physical inactivity, education, income, family history of ischaemic vascular disease, and in women also for postmenopausal status and hormonal replacement therapy. P values are for interaction between presence or absence of xanthelasmata and cardiovascular risk factors on risk of myocardial infarction, ischaemic heart disease, and total death. Within strata of risk factors, people without xanthelasmata (reference group) have hazard ratio=1 and are not shown.